Norwegian radiopharmaceutical developer Oncoinvent is highlighting that the first colorectal cancer patient has been treated in a clinical trial of the company's Radspherin drug candidate.
The RAD-18-002 phase 2A trial is designed to assess the safety, tolerability, and antitumor activity of the drug candidate, an alpha-emitting radionuclide therapy. Radspherin is administered into the intraperitoneal cavity in patients with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Oncoinvent said study goals include survival benefit as well as acute and long-term safety of Radspherin. The study is being conducted at the Radium Hospital in Oslo, Norway, and the Uppsala University Hospital in Uppsala, Sweden. It aims to include a total of 30 patients.
